Bradley Duffy

Array ( [id] => 11177994 [patent_doc_number] => 09409979 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-08-09 [patent_title] => 'Acceptor framework for CDR grafting' [patent_app_type] => utility [patent_app_number] => 14/644441 [patent_app_country] => US [patent_app_date] => 2015-03-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 10333 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 17 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14644441 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11364067 [patent_doc_number] => 20170002046 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-01-05 [patent_title] => 'PROTEINS COMPRISING BINDING REGIONS, SHIGA TOXIN A SUBUNIT EFFECTOR REGIONS, AND CARBOXY-TERMINAL, ENDOPLASMIC RETICULUM LOCALIZATION SIGNAL MOTIFS' [patent_app_type] => utility [patent_app_number] => 15/125142 [patent_app_country] => US [patent_app_date] => 2015-03-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 51815 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 7 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15125142 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13675189 [patent_doc_number] => 20160376328 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-12-29 [patent_title] => PROTEINS COMPRISING AMINO-TERMINAL PROXIMAL SHIGA TOXIN A SUBUNIT EFFECTOR REGIONS AND CELL-TARGETING IMMUNOGLOBULIN-TYPE BINDING REGIONS [patent_app_type] => utility [patent_app_number] => 15/125126 [patent_app_country] => US [patent_app_date] => 2015-03-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 45302 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15125126 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12106305 [patent_doc_number] => 09862775 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-01-09 [patent_title] => 'Monoclonal antibody which specifically recognizes B cell lymphoma and use thereof' [patent_app_type] => utility [patent_app_number] => 14/639679 [patent_app_country] => US [patent_app_date] => 2015-03-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 12 [patent_no_of_words] => 13182 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 108 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14639679 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12106305 [patent_doc_number] => 09862775 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-01-09 [patent_title] => 'Monoclonal antibody which specifically recognizes B cell lymphoma and use thereof' [patent_app_type] => utility [patent_app_number] => 14/639679 [patent_app_country] => US [patent_app_date] => 2015-03-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 12 [patent_no_of_words] => 13182 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 108 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14639679 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10354953 [patent_doc_number] => 20150239958 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-08-27 [patent_title] => 'PROCESS FOR THE MODULATION OF THE ANTAGONISTIC ACTIVITY OF A MONOCLONAL ANTIBODY' [patent_app_type] => utility [patent_app_number] => 14/631301 [patent_app_country] => US [patent_app_date] => 2015-02-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 15 [patent_no_of_words] => 14803 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14631301 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10529021 [patent_doc_number] => 09255149 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-02-09 [patent_title] => 'Cytotoxic immunoglobulin' [patent_app_type] => utility [patent_app_number] => 14/629760 [patent_app_country] => US [patent_app_date] => 2015-02-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 27 [patent_figures_cnt] => 49 [patent_no_of_words] => 32366 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 80 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14629760 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10483322 [patent_doc_number] => 20150368341 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-12-24 [patent_title] => 'POLYPEPTIDES AND ANTIBODIES DERIVED FROM CHRONIC LYMPHOCYTIC LEUKEMIA CELLS AND USES THEREOF' [patent_app_type] => utility [patent_app_number] => 14/630262 [patent_app_country] => US [patent_app_date] => 2015-02-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 55 [patent_figures_cnt] => 55 [patent_no_of_words] => 24211 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14630262 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10980006 [patent_doc_number] => 20160176950 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-06-23 [patent_title] => 'Polypeptides With Enhanced Anti-Inflammatory And Decreased Cytotoxic Properties And Relating Methods' [patent_app_type] => utility [patent_app_number] => 14/624483 [patent_app_country] => US [patent_app_date] => 2015-02-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 12 [patent_no_of_words] => 15732 [patent_no_of_claims] => 36 [patent_no_of_ind_claims] => 8 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14624483 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10292255 [patent_doc_number] => 20150177253 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-06-25 [patent_title] => 'TUMOR SUPPRESSOR DESIGNATED TS10Q23.3' [patent_app_type] => utility [patent_app_number] => 14/618861 [patent_app_country] => US [patent_app_date] => 2015-02-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 43 [patent_figures_cnt] => 43 [patent_no_of_words] => 56476 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14618861 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11107643 [patent_doc_number] => 20160304613 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-10-20 [patent_title] => 'NEUROPILIN ANTAGONISTS' [patent_app_type] => utility [patent_app_number] => 14/616415 [patent_app_country] => US [patent_app_date] => 2015-02-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 13 [patent_no_of_words] => 32830 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14616415 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11901995 [patent_doc_number] => 09771419 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-09-26 [patent_title] => 'Antagonistic human light-specific human monoclonal antibodies' [patent_app_type] => utility [patent_app_number] => 14/611965 [patent_app_country] => US [patent_app_date] => 2015-02-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 41 [patent_figures_cnt] => 58 [patent_no_of_words] => 69199 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 218 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14611965 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11290497 [patent_doc_number] => 20160340429 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-11-24 [patent_title] => 'IMMUNOMODULATORY AGENTS' [patent_app_type] => utility [patent_app_number] => 15/111102 [patent_app_country] => US [patent_app_date] => 2015-01-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 30 [patent_figures_cnt] => 30 [patent_no_of_words] => 12448 [patent_no_of_claims] => 34 [patent_no_of_ind_claims] => 7 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15111102 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10267183 [patent_doc_number] => 20150152180 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-06-04 [patent_title] => 'PD-1 SPECIFIC ANTIBODIES AND USES THEREOF' [patent_app_type] => utility [patent_app_number] => 14/588538 [patent_app_country] => US [patent_app_date] => 2015-01-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 17 [patent_figures_cnt] => 17 [patent_no_of_words] => 11390 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14588538 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10412689 [patent_doc_number] => 20150297697 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-10-22 [patent_title] => 'CANCER-ASSOCIATED ANTIGEN RELATED APPLICATIONS' [patent_app_type] => utility [patent_app_number] => 14/575007 [patent_app_country] => US [patent_app_date] => 2014-12-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 18 [patent_figures_cnt] => 18 [patent_no_of_words] => 25273 [patent_no_of_claims] => 26 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14575007 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15483261 [patent_doc_number] => 10556963 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-02-11 [patent_title] => Means and methods for counteracting myeloproliferative or lymphoproliferative disorders [patent_app_type] => utility [patent_app_number] => 15/105076 [patent_app_country] => US [patent_app_date] => 2014-12-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 48 [patent_figures_cnt] => 27 [patent_no_of_words] => 39567 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 87 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15105076 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10399419 [patent_doc_number] => 20150284428 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-10-08 [patent_title] => 'METHODS AND AGENTS FOR THE TREATMENT OF CANCER' [patent_app_type] => utility [patent_app_number] => 14/569321 [patent_app_country] => US [patent_app_date] => 2014-12-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 20 [patent_figures_cnt] => 20 [patent_no_of_words] => 15287 [patent_no_of_claims] => 85 [patent_no_of_ind_claims] => 24 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14569321 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10233187 [patent_doc_number] => 20150118181 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-04-30 [patent_title] => 'Concurrent Chemotherapy and Immunotherapy' [patent_app_type] => utility [patent_app_number] => 14/564132 [patent_app_country] => US [patent_app_date] => 2014-12-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6539 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14564132 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11100913 [patent_doc_number] => 20160297883 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-10-13 [patent_title] => 'G-PROTEIN COUPLED RECEPTOR AGONISTS AND METHODS' [patent_app_type] => utility [patent_app_number] => 15/101566 [patent_app_country] => US [patent_app_date] => 2014-12-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 44 [patent_figures_cnt] => 44 [patent_no_of_words] => 17041 [patent_no_of_claims] => 48 [patent_no_of_ind_claims] => 24 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15101566 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11809721 [patent_doc_number] => 09714281 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-07-25 [patent_title] => 'Fibronectin based scaffold domain proteins that bind IL-23' [patent_app_type] => utility [patent_app_number] => 14/553379 [patent_app_country] => US [patent_app_date] => 2014-11-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 33 [patent_figures_cnt] => 27 [patent_no_of_words] => 23273 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 8 [patent_words_short_claim] => 16 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14553379 [rel_patent_id] =>[rel_patent_doc_number] =>)